Allarity Therapeutics, Inc. (ALLR) · Nov 19, 2026 · Other events

Allarity patent extends stenoparib dosing protection to 2045

36 patent claims — Twice-daily stenoparib dosing protected into 2045

Allarity’s new patent protects stenoparib’s twice-daily dosing through 2045, strengthening its Phase 2 strategy without changing the clinical risk.

Allarity is a cash-constrained Phase 2 biotech advancing stenoparib through an expanded ovarian-cancer study and a separate small-cell-lung-cancer trial; it ended September with $24.1 million in cash and restricted cash. The filing adds a meaningful layer of commercial protection around the development plan. The 36 claims cover the twice-daily regimen Allarity says it intends to take toward pivotal trials, along with use in ovarian and other solid tumors. 〔0〕 Protection extending into 2045 also complements the company’s earlier stenoparib-specific companion-diagnostic patent. 〔1〕

The signal is positive, but it is infrastructure—not validation. This improves the asset’s potential partnering and exclusivity story, especially because the protected regimen is central to the current Phase 2 program. But the filing produces no new response, survival, safety, enrollment, regulatory, or financing milestone; patent value still depends on stenoparib generating convincing clinical data and the claims surviving any challenge. The company’s recent patent and DRP announcements make the broader IP strategy partly known, so the new information is mainly the specific dosing coverage and longer protection period.

Bottom line: This modestly strengthens Allarity’s stenoparib development and partnering setup, but it does not materially de-risk the drug itself. The core story remains a Phase 2 clinical gamble awaiting efficacy evidence.

Original filing on SEC EDGAR

More Allarity Therapeutics, Inc. news

Allarity patent extends stenoparib dosing protection to 2045 | ALLR Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.